Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership aims to expand the sales network supporting Zynrelef (bupivacaine and meloxicam) extended-release solution, the first and only dual-acting local anesthetic, for post-operative pain.
Lead Product(s): Bupivacaine,Meloxicam
Therapeutic Area: Neurology Product Name: Zynrelef
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: CrossLink Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 07, 2024
Details:
ZYNRELEF is the first and only dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of nonsteroidal anti-inflammatory drug meloxicam.
Lead Product(s): Bupivacaine,Meloxicam
Therapeutic Area: Neurology Product Name: Zynrelef
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 29, 2022
Details:
Administered via a single 30-second IV injection, APONVIE(aprepitant) reaches drug levels associated with ≥97% receptor occupancy in the brain within five minutes and maintains therapeutic plasma concentrations for at least 48 hours.
Lead Product(s): Aprepitant
Therapeutic Area: Gastroenterology Product Name: Aponvie
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2022
Details:
ZYNRELEF (bupivacaine) is first and only therapy for pain management to be rigorously tested demonstrated superiority to bupivacaine solution, and sustained postoperative pain relief for up to 72 hours and decreased need for opioids, with more patients opioid-free.
Lead Product(s): Bupivacaine,Meloxicam
Therapeutic Area: Neurology Product Name: Zynrelef
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2022
Details:
New interim data from Phase 2 study suggests ZYNRELEF (bupivacaine) was well-tolerated and may effectively manage postpartum pain and minimize postoperative opioid use in women undergoing Caesarean sections.
Lead Product(s): Bupivacaine,Meloxicam
Therapeutic Area: Neurology Product Name: Zynrelef
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Details:
ZYNRELEF is first and only therapy of dual-acting fixed-dose combination of local anesthetic bupivacaine and a low dose of meloxicam, for postoperative pain management to be rigorously tested in Phase 3 studies and demonstrate superiority to bupivacaine solution.
Lead Product(s): Bupivacaine,Meloxicam
Therapeutic Area: Neurology Product Name: Zynrelef
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2022
Details:
ZYNRELEF is an extended-release solution of bupivacaine and meloxicam that is indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty.
Lead Product(s): Bupivacaine,Meloxicam
Therapeutic Area: Neurology Product Name: Zynrelef
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2021
Details:
Proceeds from the sale of the Notes will be used for the commercial launch of ZYNRELEFTM (bupivacaine and meloxicam) extended-release solution, as well as for general working capital.
Lead Product(s): Bupivacaine,Meloxicam
Therapeutic Area: Neurology Product Name: Zynrelef
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: J. Wood Capital Advisors LLC
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Financing May 25, 2021
Details:
ZYNRELEF, the first and only extended-release dual-acting local anesthetic (DALA), delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam.
Lead Product(s): Bupivacaine,Meloxicam
Therapeutic Area: Neurology Product Name: Zynrelef
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2021
Details:
The NDA for HTX-011 was resubmitted based on the outcome and final minutes of a Type A End-of-Review meeting with the FDA in September, which was conducted to obtain clarity on the information needed to address the Complete Response Letter (CRL) issued by the FDA in June 2020.
Lead Product(s): Bupivacaine,Meloxicam
Therapeutic Area: Neurology Product Name: Zynrelef
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020